Cargando…
Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline
Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systemat...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774918/ https://www.ncbi.nlm.nih.gov/pubmed/35049696 http://dx.doi.org/10.3390/curroncol29010022 |
_version_ | 1784636458489872384 |
---|---|
author | Hirte, Hal Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie |
author_facet | Hirte, Hal Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie |
author_sort | Hirte, Hal |
collection | PubMed |
description | Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients. |
format | Online Article Text |
id | pubmed-8774918 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87749182022-01-21 Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline Hirte, Hal Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie Curr Oncol Guidelines Background: This study aims to provide guidance for the use of neoadjuvant and adjuvant systemic therapy in women with newly diagnosed stage II–IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma. Methods: EMBASE, MEDLINE, and Cochrane Library were investigated for relevant systematic reviews and phase III trials. Articles focusing on consolidation and maintenance therapies were excluded. Results: For women with potentially resectable disease, primary cytoreductive surgery, followed by six to eight cycles of intravenous three-weekly paclitaxel and carboplatin is recommended. For those with a high-risk profile for primary cytoreductive surgery, neoadjuvant chemotherapy can be an option. Adjuvant chemotherapy with six cycles of dose-dense weekly paclitaxel plus three-weekly carboplatin can be considered for women of Japanese descent. In women with stage III or IV disease, the incorporation of bevacizumab concurrent with paclitaxel and carboplatin is not recommended for use as adjuvant therapy unless bevacizumab is continued as maintenance therapy. Intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel can be considered for stage III optimally debulked women who did not receive neoadjuvant chemotherapy. However, intraperitoneal administration of chemotherapy with bevacizumab should not be considered as an option for stage II–IV optimally debulked women. Discussion: The recommendations represent a current standard of care that is feasible to implement and valued by both clinicians and patients. MDPI 2022-01-08 /pmc/articles/PMC8774918/ /pubmed/35049696 http://dx.doi.org/10.3390/curroncol29010022 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Guidelines Hirte, Hal Poon, Raymond Yao, Xiaomei May, Taymaa Ethier, Josee-Lyne Petz, Lauri Speakman, Jane Elit, Laurie Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title | Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title_full | Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title_fullStr | Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title_full_unstemmed | Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title_short | Neoadjuvant and Adjuvant Systemic Therapy for Newly Diagnosed Stage II–IV Epithelial Ovary, Fallopian Tube, or Primary Peritoneal Carcinoma: A Practice Guideline |
title_sort | neoadjuvant and adjuvant systemic therapy for newly diagnosed stage ii–iv epithelial ovary, fallopian tube, or primary peritoneal carcinoma: a practice guideline |
topic | Guidelines |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8774918/ https://www.ncbi.nlm.nih.gov/pubmed/35049696 http://dx.doi.org/10.3390/curroncol29010022 |
work_keys_str_mv | AT hirtehal neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT poonraymond neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT yaoxiaomei neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT maytaymaa neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT ethierjoseelyne neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT petzlauri neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT speakmanjane neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline AT elitlaurie neoadjuvantandadjuvantsystemictherapyfornewlydiagnosedstageiiivepithelialovaryfallopiantubeorprimaryperitonealcarcinomaapracticeguideline |